Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Clinical trials sponsored by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., explained in plain language.
Biopharmaceutical company focused on antibody-drug conjugates (ADCs) and oncology.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug duo aims to slow advanced lung cancer in first-line trial Results expected Nov 2026 (estimated)
- New hope for advanced breast cancer: A166 takes on T-DM1 in head-to-head trial Results expected Nov 2026 (estimated)
- New hope for lung cancer patients who can't use standard immunotherapy alone Results expected Dec 2026 (estimated)
- New cancer drug SKB571 enters first human tests Results expected Dec 2026 (estimated)
- New drug SKB264 targets Hard-to-Treat cancers in Mid-Stage trial Results expected Dec 2026 (estimated)
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control CompletedThis phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups …
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug SKB410 enters human testing for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tests a new drug called SKB410 in about 54 adults with advanced solid tumors who have no standard treatment options left. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants receive multiple doses…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody shows promise in early trial for tough colorectal cancer
Disease control CompletedThis early-stage study tested a new antibody drug (similar to cetuximab) in 18 people with advanced colorectal cancer that had stopped responding to standard treatments. The main goal was to check safety and how the drug moves through the body. Participants received one of two do…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug A140 challenges standard treatment for colorectal cancer
Disease control CompletedThis study tested whether a new drug called A140 works as well as the standard drug Erbitux for people with a certain type of advanced colorectal cancer (RAS wild-type). Both drugs were given together with chemotherapy. The trial involved 688 adults and measured how many patients…
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase 1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New drug shows promise for Tough-to-Treat throat cancer
Disease control CompletedThis phase 2 trial tested a drug called KL-A167 in 153 adults with recurrent or metastatic nasopharyngeal carcinoma (a type of throat cancer). Participants received the drug by IV every two weeks. The main goal was to see how many patients' tumors shrank or disappeared. The study…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug shows promise for Tough-to-Treat hodgkin lymphoma
Disease control CompletedThis phase 2 trial tested a drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or not responded to prior treatments. Participants received the drug intravenously every two weeks. The main goal was to see how many patients' tumors shrank or disappe…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC